If your patient is a unilateral myope, sometimes the myopic eye is the easier one to manage! This case study explores the options to appropriately diagnose, track and manage the non-myopic eye in a unilateral myope – where the non-myopic eye seems to be progressing faster than the myopic eye treated with orthokeratology.
Most clinicians are aware of myopia risk factors such as family history and visual environment, but how about axial length? This article explores how we can use the current axial length value, change in axial length, axial length growth charts, and another metric, the axial-length-to-corneal-radius (AL/CR ratio), to predict risk of a child developing myopia.
Is a 3-year-old too young for low-dose atropine treatment? What about if they’re a pre-myope? Learn more about balancing proactive management with the research evidence and clinical considerations.
In 2021, the World Council of Optometry (WCO) passed a resolution that publicly declares support for myopia management as standard of care. Since then, CooperVision has supported the WCO to empower eye care professionals to put this into action, with a multilingual online resource launched and more being added throughout 2022. Explore and learn more here.
Myopia management starts with identifying pre-myopes and commencing the discussion with parents, so that future myopia control strategies can be successfully recommended. In our Clinical Leader Case Study format, read how Indie Grewal approached parent communication to smooth the way for eventual myopia control contact lens fitting.
Adults with myopia may not understand that they have more than just a problem seeing clearly. We discuss genetic risk in glaucoma and macular degeneration – are you doing the same for myopia? How can we talk to myopic adults about risks for their children and support them to take action?
A country-wide intervention to increase outdoor time in 5-6 year olds resulted in the prevalence of myopia decreasing from 15% in the 2014 cohort (before the intervention) to 8% in 2016 cohort (exposed to the intervention for up to two years) and was stable for three years thereafter. Increasing outdoor time works!
Pre-myopes can be readily identified, and best practice dictates that we should offer some form of intervention to help delay the onset of myopia. In this case we discuss the features of a pre-myope and an example in a 5 year old patient who satisfies the refractive criteria for pre-myopia, and has a strong family history of myopia.
Esophoria at near is a risk factor for myopia development and progression. Does it need to be managed in an emmetropic patient without symptoms? Is this patient a pre-myope, and how should this factor into management? Read this interesting clinical case, where colleagues discuss whether to intervene or not, and how to potentially manage both myopia risk and binocular vision.
If our goal is to manage myopia, preventing its onset should be an even more valuable target. How can we consistently identify pre-myopes, explain the concern to parents, and how can we best manage them based on the evidence?
